Brief: Akari Therapeutics Announces Acceleration Of Phase 3 Clinical Trial Of Nomacopan
13/02/2023 13:29
Feb 13 (Reuters) - Akari Therapeutics PLC AKTX.O :
* AKARI THERAPEUTICS ANNOUNCES ACCELERATION OF THE PHASE 3
CLINICAL TRIAL OF NOMACOPAN FOR TREATMENT OF PEDIATRIC HSCT-TMA
INTO PIVOTAL PART B AND ADDITION OF A NEW PIPELINE PROGRAM
DEVELOPING NOMACOPAN FOR HSCT-TMA IN ADULTS
Source text for Eikon: ID:nGNX1WyK0M
Further company coverage: AKTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics